Osteoprotegerin (OPG): A potential biomarker for adverse cardiovascular events in stable coronary artery disease.
Syed Muhammad Muneeb AkhtarAzzam AliAreeba FareedJina HasanPublished in: Health science reports (2024)
OPG's role in bone health and immune regulation has expanded to potential use as a biomarker for adverse cardiovascular events in stable coronary artery disease (CAD) patients. Despite limitations, its association with cardiovascular risks highlights its importance in risk assessment and personalized interventions.
Keyphrases
- cardiovascular events
- coronary artery disease
- human health
- risk assessment
- percutaneous coronary intervention
- coronary artery bypass grafting
- end stage renal disease
- cardiovascular disease
- newly diagnosed
- public health
- healthcare
- ejection fraction
- chronic kidney disease
- physical activity
- mental health
- peritoneal dialysis
- prognostic factors
- heavy metals
- bone mineral density
- emergency department
- heart failure
- acute coronary syndrome
- health information
- climate change
- social media
- transcatheter aortic valve replacement
- bone regeneration